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High-resolution magnetic resonance microscopy (MRM) was used
to determine regional brain volumetric changes in a mouse model
of Alzheimer’s disease. These transgenic (Tg) mice overexpress
human mutant amyloid precursor protein (APP) V717F under con-
trol of platelet-derived growth factor promoter (PDAPP mice), and
cortical and hippocampal -amyloid (A) deposits accumulate in
heterozygotes after 8–10 mos. We used MRM to obtain 3D volu-
metric data on mouse brains imaged in their skulls to define
genotype- and age-related changes. Hippocampal, cerebellar, and
brain volumes and corpus callosum length were quantified in 40-,
100-, 365-, and 630-day-old mice. Measurements taken at age 100
days, before A deposition, revealed a 12.3% reduction of hip-
pocampus volume in Tg mice compared with WT controls. This
reduction persisted without progression to age 21 mos. A signif-
icant 18% increase in hippocampal volume occurred between 40
and 630 days in WT mice, and no corresponding significant increase
occurred in Tg mice. Cavalieri volume estimates of hippocampal
subfields from 100-day-old Tg mice further localized a 28% volume
deficit in the dentate gyrus. In addition, corpus callosum length
was reduced by25% in Tg mice at all ages analyzed. In summary,
reduced hippocampal volume and corpus callosum length can be
detected by MRM before A deposition. We conclude that over-
expression of APP and amyloid may initiate pathologic changes
before the appearance of plaques, suggesting novel targets for the
treatment of Alzheimer’s disease and further reinforcing the need
for early diagnosis and treatment.
The essential neuropathologic features of Alzheimer’s disease(AD) include the progressive deposition of amyloid plaques
and neurofibrillary tangles in neocortical and hippocampal
structures and a parallel global decrease in cortical volume (1, 2).
Extensive data from analysis of postmortem human brain and
mouse models of AD associate the neuropathology of AD with
alterations in the expression, distribution, and deposition of 
amyloid protein (A). In AD brains, A levels are increased, and
the protein can be found in fibrillar chains within compact
plaques, aggregated in diffuse plaques, or as oligomers and
monomers in regions outside of plaques (3–6). Some of the
known human mutations associated with AD affect the process-
ing or cleavage of amyloid precursor protein (APP) and can
cause increased A levels or increase the relative amount of the
primary plaque component A1–42 compared with A1–40 (3,
5–10). Other human mutations have been identified within the
coding region of A1–42, which can increase A neurotoxicity
(11). Transgenic (Tg) mouse models have shown that high levels
of A can cause AD-like amyloid plaque pathology. Tg mice that
overexpress APP have some but not all deficits observed in AD
(12, 13). Other Tg mouse models that have mutations associated
with AD resulting in up-regulation of A production have many,
but not all, of the observed deficits seen in AD, including
reduced hippocampal volume, reduced synapse densities, plaque
formation, and cognitive deficits (14–21).
In one mouse model of familial early-onset AD, mice express
the human V717F mutation (22) in the APP gene under the
control of the platelet-derived growth factor- promoter
(PDAPP mice) (15). In heterozygous mice, A-containing
plaques begin to accumulate after 8–10 mos. Hippocampal
synaptophysin and mitogen-activated protein 2 immunoreactiv-
ity are reduced at this time point and beyond (15, 16). A-
containing plaques accumulate substantially in the hippocampus
and neocortex of aged 18- to 20-mo-old mice, corresponding to
behavioral deficits associated with the memory loss seen in such
aged mice (23). Passive and active vaccination with anti-A
antibodies has been reported to reduce tissue A levels (24),
demonstrating the potential for testing therapeutic strategies for
AD with this model. However, there is currently insufficient
rigorous quantitative data from PDAPP  (Tg) mice to dem-
onstrate whether additional therapeutic strategies may be ad-
vantageous. Specifically, we sought to define the earliest time
point at which volumetric alterations could be detected, and
whether such changes were progressive.
We initially hypothesized that a hippocampal volume deficit
would be detected by magnetic resonance microscopy (MRM) in
aged 21-mo-old Tg mice, corresponding to a time when plaque
accumulation and behavioral deficits are maximally evident. We
anticipated that such hippocampal volume changes would not be
evident in younger 40- or 100-day-old Tg mice, corresponding to
time points before significant plaque deposition.
To obtain accurate estimates of volumes of intracerebral struc-
tures, we used MRM to acquire high-resolution 3D digital datasets
with which to identify and quantify the volume of defined brain
regions without the distortion associated with brain removal and
sectioning. The MRM technique has not been previously used to
quantify volume changes in mouse models of AD. Accordingly, we
applied MRM to determine the volumes of the hippocampus, brain,
and cerebellum of Tg mice before removal of the brain from the
skull at four developmental ages: 40 days, 100 days, 12 mos (365
days), and 21 mos (630 days), in comparison to similar measure-
ments in WT mice of the same strain.
Materials and Methods
Mice. Heterozygous male PDAPP and WT littermate mice
(Taconic Farms) were used for these studies. Twelve 40-day-old
(six Tg, six WT), 13 100-day-old (six Tg, seven WT), 12 12-mo-
old (five Tg, seven WT), and 12 21-mo-old (six Tg, six WT) mice
were used for MRM analysis; a subset of the identical 100-day-
Abbreviations: AD, Alzheimer’s disease; APP, amyloid precursor protein; A, -amyloid
protein; MRM, magnetic resonance microscopy; MANOVA, multiple ANOVA; Tg,
transgenic.
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old mice was used for stereologic volume estimation of the
hippocampus (five Tg, six WT). Mouse body weights were
monitored at all ages, and no significant difference was found
between groups (Fig. 6, which is published as supporting infor-
mation on the PNAS web site, www.pnas.org).
Tissue Preparation. Mice were anesthetized with avertin (0.5 mgg
body weight) and transcardially perfused at 15 mlmin, first with
20 ml of 1% paraformaldehyde in 0.1 M NaPO4 buffer, pH 7.4,
at room temperature, followed by 100 ml of 4% paraformalde-
hyde in the same buffer at 4°C. The mouse head was removed
and postfixed in 4% paraformaldehyde for 5–8 h, then trans-
ferred to buffer and stored at 4°C. For stereologic volume
estimation, the brains were dissected, cryoprotected with 30%
sucrose, frozen, and stored at 20°C. Fifty-micrometer sections
were cut with a sliding microtome, mounted on gelatin-coated
slides, and stained with 0.1% thionin followed by 0.24% cresyl
violet.
MRI. T2-weighted spin-echo 3D datasets were acquired from the
mouse heads (brain intact within the skull) by using a vertical
bore 11.7 T Bruker Avance imaging spectrometer with a micro-
imaging gradient insert and 25 mm birdcage RF coil (Bruker,
Billerica, MA). Samples were immersed in fomblin (Ausimont,
Thorofare, NJ) and maintained at 4°C. In each case, low-
resolution (110-m isotropic resolution) and high-resolution
(55-m isotropic resolution) data sets were acquired. Imaging
parameters: 3D spin echo Rapid Acquisition with Relaxation
Enhancement (RARE) (25) acquisition protocol, matrix dimen-
sions  256  128  128 and 512  256  256 (high-resolution
set); field of view  2.8  1.4  1.4 cm; repetition time (TR) 
3.0 s and 1.5 s (high-resolution set); effective echo time (TE) 
18.3 and 12.4 ms (high-resolution set); RARE factor  4,
number averages  2 and 1 (high-resolution set). Total imaging
time per head was 6 h 53 min (low-resolution set) and 13 h 45
min (high-resolution set).
Volume Determination. 3D MRM files with matrix dimensions 
256  128  128 were analyzed by using AMIRA software (TGS,
Richmond, TX) with the observer blind to genotypes. The
acquisition scheme described above provided clear whitegray
matter borders that were confirmed by histological analyses. The
borders of the brain, cerebellum, and hippocampus were drawn
and checked in three orthogonal planes to ensure accuracy. The
rostral border of the cerebellum included the flocculus, middle
cerebellar peduncle, and central lobule two, and the ventral
border was drawn dorsal to the fourth ventricle. The border of
the hippocampus was drawn at the graywhite matter border
with the fimbriacorpus callosum. The border of the brain was
drawn at the pial surface (including olfactory bulbs), and the
medullaspinal cord border was drawn down from the most
caudal point of the cerebellum. Brain volumes reported exclude
the volume of hippocampus and cerebellum. For each brain, the
hippocampus was segmented three times, and the mean of three
trials was used as the value for hippocampal volume. After image
segmentation, borders were smoothed (AMIRA smooth setting of
‘‘3’’), and a generalized marching cubes (GMC) calculation was
performed to generate a 3D surface reconstruction to obtain
volumes (all means and coefficients of variance are presented in
Table 1, which is published as supporting information on the
PNAS web site). A voxel count was also performed, and volumes
derived from voxel counts and GMC calculation were similar
(data not shown). In addition, the mean hippocampal volume
obtained from the 256  128  128 matrix file from 18 brains
was compared with hippocampal volume obtained from one
segmentation trial from 512 256 256 matrix file of the same
brains, and the volumes were similar and were correlated (Fig.
7, which is published as supporting information on the PNAS
web site).
Cavalieri Volume Estimation. Volume estimation using the Cava-
lieri principle on Tg (n 5) and WT (n 6) mice was performed
with STEREO INVESTIGATOR software (MicroBrightField, Will-
iston, VT) driving a motorized stage (Ludl, Hawthorne, NY) on
a Zeiss Axioplan 2ie with a 5 objective (numerical aperture 
0.25). The final magnification used for grid point counting was
190. Before Cavalieri analysis, a Nissl-stained atlas was gen-
erated with contours drawn for dentate gyrus, CA1CA2, CA3,
and subiculum subfields in the hippocampus, which was used as
a guide for all analyses. Cavalieri analysis was performed with
the investigator blind to genotype. Volumes of each subfield
were estimated by using a one-in-four systematic random series
of 50-m Nissl-stained sections using a 200-m2 point-counting
grid. Between 350 and 1,051 grid points from 6 and 16 sections
were counted for each subfield per hippocampus, which pro-
vided coefficient of error (CE) estimates of 0.1. Means and
Gunderson CE estimates are provided (Table 2, which is pub-
lished as supporting information on the PNAS web site).
Corpus Callosum Length Measurement. By using 512  256  256
MRM files, a point was placed at the most rostral position of the
genu of the corpus callosum where white matter appeared
continuous across the midline. A second point was placed at the
most caudal position of the splenium of the corpus callosum,
where white matter last appears as continuous. The length of the
line between these two points was used to determine the corpus
callosum length.
Statistical Analysis. All volume data along with corpus callosum
length were simultaneously analyzed with multiple ANOVA
(MANOVA) followed by Bonferroni post hoc test. Tukey’s
honestly significant difference post hoc test was also used and
provided statistical significance of pairwise comparisons that
matched results obtained with Bonferroni’s (data not shown).
Cavalieri volume estimations of Tg hippocampal subfield vol-
umes were compared with WT subfield volumes by using an
unpaired Student’s t test.
Results
MRM Analysis. The MRM acquisition protocol provided an in-
plane resolution of100 m (Fig. 1). From these 3D image files,
Fig. 1. Anatomical structures visible with MRM. (a–c) Examples of structures
visible with high-resolution files (512  256  256 matrix). (a) Pencil fibers in
the striatum (arrow) are visible, as well as the hippocampus (H) in a sagittal
section. (b) Corpus callosum (arrow) and cerebellum (C) are visible in this
midsagittal plane. (c) Corpus callosum (arrow) and hippocampus (H) are visible
in a coronal plane. (d) A coronal plane of a lower-resolution file (256 128
128 matrix), where corpus callosum (arrow) and hippocampus (H) are clearly
visible, compared with a matching coronal plane of a high-resolution file of
the same brain seen in c. (Bar  2 mm.)
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the hippocampus, cerebellum, and remaining brain were easily
detected and segmented. Once complete, manual segmentation
of each structure was checked for accuracy in three orthogonal
planes, and surface reconstructions and corresponding volumes
of hippocampus, cerebellum, and ‘‘rest-of-brain’’ (excluding
hippocampus and cerebellum) were obtained (Fig. 2). MRM-
derived volume and coefficients of variance values are provided
(Table 1), and comparison of volumes obtained with analysis of
low- vs. high-resolution files is also provided (Fig. 7).
A MANOVA showed a main effect of genotype on hippocam-
pal volume [F (1, 49)  31, P  0.001]. A Bonferroni post hoc
test showed there was no volume difference detectable when
comparing Tg and WT mice at 40 days. However, hippocampal
volume was statistically significantly smaller by 12.3% in Tg vs.
WT mice at 100 days (Fig. 3). This early time point precedes any
accumulation of A and precedes the formation of A-
containing plaques. This loss of hippocampal volume begins
between 40 and 100 days of age, but as shown for the two older
sampling periods, the volume loss does not progress between
ages 100 and 630 days. At 630 days, there was a significant 13.7%
volume deficit in Tg hippocampal volume that was not statisti-
cally different from volumes obtained at 100 or 365 days.
We also unexpectedly found continued growth in hippocampal
volume in WT mice between 40 and 100 days. MANOVA
showed a main effect of age on hippocampal volume [F (3, 49)
11.5, P  0.001]. There was an 18% increase in hippocampal
volume in WT mice between 40 and 630 days of age. The post
hoc analyses showed that the hippocampus of 40-day-old WT
mice was smaller than that of 100-, 365-, or 630-day-old WT
mice. However, the Tg mice showed no significant growth during
this same time frame (Fig. 3).
MANOVA also showed a main effect of genotype on brain
volume [F (3, 49)  10.8, P  0.01]; however, post hoc tests did
not detect a significant deficit in Tg mice at any age. Finally,
there was no change in cerebellar volume detected between
genotypes or across time within a genotype (Fig. 3).
Cavalieri Volume Estimation. In addition to MRM analysis, five Tg
and six WT 100-day-old animals that had been analyzed with
MRM were also histologically prepared for stereologic volume
estimation of hippocampal subfields from Nissl-stained sections.
This additional analysis allowed, (i) comparison of MRM-
derived volumes versus Cavalieri volume estimations; and
(ii) analysis of hippocampal subfields to localize further possible
regions of volume loss within the hippocampus. Total hippocam-
pal volumes obtained from MRM analysis were highly correlated
with the total hippocampal volumes obtained from Cavalieri
volume estimates of the same brains (r2  0.57, P  0.007, n 
Fig. 2. Image segmentation and surface reconstruction were used to obtain
volumes of brain structures. (a–c) Examples of image segmentation of hip-
pocampus on a 3D volumetric MRM file. Accurate borders were drawn and
verified in three dimensions simultaneously as shown in the horizontal (a),
coronal (b), and sagittal (c) planes. 3D surface reconstructions were generated
from the image segmentation of the hippocampus (d), as well as the cerebel-
lum (e) and brain ( f). The brain volumes reported excluded the volumes of the
hippocampus and cerebellum. (g) 3D surface reconstructions within a 3D
volumetric MRM file. Note the brain is undissected and still lies within the
mouse head. (Bar  2 mm.)
Fig. 3. Quantitative analysis of MRM images of Tg and WT mice at 40, 100,
365, and 630 days of age. (a) Bonferroni’s post hoc test showed hippocampal
volumes of Tg and WT mice were not different at 40 days, but Tg were
significantly smaller at 100 and 630 days (21 mos) (*, P 0.05). WT hippocam-
pal volumes at 100, 365, and 630 days were significantly larger than 40-day WT
volumes (†, P  0.05). No statistically significant volume changes occurred in
the Tg mice over time. (b) Although there was a main effect of genotype on
brain volume, a post hoc test showed that no specific time point was signifi-
cantly reduced in Tg compared with WT mice. (c) Cerebellum volumes did not
differ between groups and did not change over time. (d) Corpus callosum
length was significantly reduced in Tg mice at all time points (*, P  0.0001).
Corpus callosum lengths in WT mice at 100, 365, and 630 days were signifi-
cantly longer compared with 40 days WT (†, P 0.05). Corpus callosum length
in Tg mice did not significantly change over time. (Error bars, SEM.)
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11) (Fig. 4). Cavalieri volume estimation also detected a signif-
icant decrease in total hippocampal volume of 12.6% at 100 days
in Tg mice compared with WT by an unpaired Student’s t test
(P  0.04), which corresponds closely with the 12.3% volume
deficit obtained with MRM (P  0.001 by unpaired Student’s t
test to compare Tg vs. WT) (Fig. 4).
Hippocampal volumes obtained from MRM analysis were
slightly smaller and had a much tighter interindividual range
(i.e., less variability) compared with the Cavalieri-obtained
volumes on the sectioned brains. The SD of hippocampal
volumes within groups was smaller from MRM analysis (Tg
SD  0.61, WT SD  0.41) compared with Cavalieri (Tg SD 
1.76, WT SD  1.75).
The Cavalieri analysis also provided valuable hippocampal
subfield volumes based on anatomical borders detectable by
microscopic analysis with Nissl stain, which included CA1CA2,
CA3, subiculum, and dentate gyrus. Analysis of the dentate
gyrus as measured included both the granule cell and molecular
layers but did not include the hilus. Cavalieri analysis demon-
strated a significant and selective volume reduction of 28% in Tg
dentate gyrus compared with WT (Fig. 5). It is important to
emphasize that the volume reduction observed was specific to Tg
dentate gyrus. No significant volume reduction was observed in
the CA1, CA3, and subiculum subfields of the Tg hippocampus
in the 100-day animal analyses (subfield volume fractions given
in Fig. 8, which is published as supporting information on the
PNAS web site).
Corpus Callosum Length. In addition to the regional volume deficits
observed, we also detected a white-matter deficit by using MRM
indicated by a shorter corpus callosum in Tg mice. MANOVA
showed a main effect of genotype on corpus callosum length
[F (1, 49) 252, P 0.0001; Fig. 3]. The corpus callosum length
was reduced at all time points examined in Tg mice. MANOVA
also showed a main effect of age on corpus callosum length
[F (3, 49)  9.7, P  0.0001; Fig. 3]. The main effect of age was
due to an increase in length over time in the WT group. There
was no progression of corpus callosum length deficit over time
observed in Tg mice. Other white matter tracts such as anterior
commissure and fornix displayed no apparent qualitative differ-
ences across Tg and WT mice (not shown).
Discussion
Contrary to our initial hypothesis, we have shown that Tg mice
exhibit a significant hippocampal volume deficit at 100 days of
age compared with WT mice, yet no such difference was
apparent at 40 days. The hippocampal volume reduction emerges
between 40 and 100 days of age and is predominantly localized
to the dentate gyrus. This volume deficit occurs before any
histologically evident accumulation of A or formation of
A-containing diffuse or compact plaques (at 6 mos, plaques
occupy 0.1% of hippocampal volume; J.F.R., unpublished
data). The hippocampal volume deficit in 100- and 630-day-old
Tg mice is not progressive and is due to a continued postnatal
increase in hippocampal volume in WT mice that does not occur
in Tg mice.
ValidationAdvantages of the MRM Method. This is the first exam-
ple, to our knowledge, of applying quantitative 3D MRM to
detect brain volume changes over time in a mouse model of AD.
Volume determination from a complete 3D hippocampal image
produced precise and reproducible data with low variation
compared with Cavalieri volume estimation. Also, to our knowl-
edge, this is the first example of a direct comparison between
MRM- and Cavalieri-derived volumes of sectioned brain. These
data confirm the value of MRM as a tool for quantifying brain
pathology in the rodent and support the notion of a dependable
relationship between MRM volume analysis and Cavalieri vol-
ume analysis for the mouse hippocampus. Cavalieri hippocampal
volumes were 10% larger than MRM volumes, perhaps due to
changes during tissue handling or storage. The quantitative
histological analysis was required to determine how pervasive
within the hippocampal formation was this loss of volume. The
Cavalieri analysis pinpointed that one subfield was selectively
Fig. 4. Comparison of 3-mo MRM-derived hippocampal volumes with Cava-
lieri volume estimation of hippocampus from the same brains. (a) A coronal
section through the hippocampus from a WT brain with a 512  256  256
matrix MRM file. (b) A Nissl-stained section through the hippocampus of the
same WT brain. (c) An example of a Nissl-stained hippocampus with a 200-m
grid overlay used for Cavalieri volume estimation. (d) The correlation between
hippocampal volumes of 11 brains derived with MRM analysis and Cavalieri
volume estimation (r2 0.57, P 0.01). Six WT brains () and five Tg brains (‚)
were used for this analysis. (e) Hippocampal volumes obtained with Cavalieri
volume estimation of 100-day Tg mice were significantly smaller com-
pared with WT mice (12.6%, *, P  0.04 with unpaired Student’s t test),
compared with the previously shown 12.3% smaller Tg hippocampal volume
obtained with MRM analysis (**, P  0.001 with unpaired Student’s t test).
Although a significant difference was found with both methods, note the
larger error bars and the higher P value using the Cavalieri method.
(Bar, 2 mm; error bars, SEM.)
Fig. 5. One hundred-day-old hippocampal subfield volume estimation. (a)
An example of a Nissl-stained 100-day WT mouse hippocampus with a 200-m
grid overlay used for Cavalieri volume estimations. Subfields are marked as
CA1 (pink circles), CA3 (green circles), and dentate gyrus (blue diamonds).
Dentate gyrus volumes were obtained excluding the hilus. (b) There was a
significantly smaller dentate gyrus (28%) in Tg (n 5) compared with WT mice
(n  6) (*, P  0.003 with unpaired Student’s t test). No other subfield was
found to be significantly different. (Error bars, SEM.)
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affected, namely the dentate gyrus. The MRM analysis also
exhibited such a consistent and accurate set of measurements
that the volume loss was apparent at the level of whole hip-
pocampus, reinforcing the utility of the MRM approach for
revealing small but meaningful pathological changes. The 15%
growth of WT mice hippocampus after 40 days has not been
quantified previously with 3D volume determination in mice but
confirms an earlier report that the wet weight of dissected mouse
hippocampus increases by 15% between 30 and 300 days of
age (26).
Neurobiologic Basis for the Anatomic Specificity of the Neuropatho-
logic Findings. This combined MRMstereologic analysis not only
established a highly specific and surprisingly early temporal
window for the detection of an inferred onset of pathology but
also targeted the region of earliest hippocampal pathology with
great precision, i.e., the molecular layer of dentate gyrus. This
decrement in volume could reflect pathology in afferents, in
dentate granule cell dendrites, or both. That the molecular layer
of the dentate gyrus exhibits such an extensive and specific loss
is particularly important, given that it is the site of termination
of the perforant path from the entorhinal cortex, a circuit that
is highly vulnerable in aging and AD (27–29). The early dentate
gyrus pathology in this mouse model is consistent with the early
pathology of the entorhinal cortex in AD (30), in that the
entorhinal cortex projects heavily to the molecular layer of the
dentate gyrus through the perforant path. This circuit will need
to be analyzed with higher-resolution techniques to define
cellular pathology associated with volume loss, but such consis-
tency with the selective vulnerability apparent in humans further
validates this mouse model of AD.
The age of onset of potentially subtle pathology and related
neuronal dysfunction in mouse models of AD is not well
characterized. These studies pinpoint hippocampal pathology in
Tg mice that is not present at 40 days but is clearly detectable in
the dentate gyrus of the hippocampus by 100 days of age.
Volume changes in PDAPP mice have not been previously
detected at this early time point with 3D volume analysis
examining the entire hippocampus. These data complement
other studies that report hippocampal electrophysiological, be-
havioral, or metabolic changes in PDAPP mice at young ages
preceding significant plaque deposition but at ages beyond 40
days old (19, 31–35). Early localized pathology may also occur in
the human brain in normal aging (28) as well as in AD (36–44).
Future studies designed to assess therapeutic interventions
should therefore consider targeting very early time points in both
animal models and humans.
Mechanisms Underlying PDAPP-Induced Neuropathology. Compari-
sons of MRM-derived hippocampal volumes demonstrate that
between 40 and 100 days of age, WT mice showed continued
growth, whereas Tg mice showed no significant growth during
the same time. Continued growth within the normal mouse
hippocampus at this stage has not been well characterized and
may indicate that maturation is still ongoing well after 40 days of
age. The negligible growth observed between 40 and 100 days in
the Tg mice may reflect the influence of increased soluble A,
before the appearance of plaques, on the normal maturation of
neurons and synapses. A can bind to neuronal receptors
(45–47), and A, whether in oligomeric or fibrillar form, can
block long-term potentiation in hippocampal neurons or cause
neuronal damage in vitro (48, 49). However, whether this inter-
action occurs in vivo in a way that blocks or degrades normal
synaptic connections remains to be tested. A can also bind
extracellular molecules that normally promote dendritic branch-
ing or extension, such as the heparan sulfate proteoglycan agrin
(50–52). Agrin is especially noteworthy because it promotes
dendritic branching, dendritic elongation, microtubule assembly,
and synaptic differentiation (53–55). If elevated levels of A
interfere with the normal function of extracellular matrix mol-
ecules such as agrin, then synaptic formation as well as main-
tenance may be impaired.
There is also evidence that A (or APP) facilitates neurite
outgrowth and synapse formation (56–59). Although only cul-
ture experiments but not in vivo models (60) support this
possibility to date, it is interesting to note that APP-deficient or
knockout mice have a corpus callosum deficit (61), as is seen in
PDAPP mice overexpressing APP, and aged APP knockout
mice have a 12% volume deficit in the dentate gyrus of the
hippocampus (60). This apparently dichotomous effect on neu-
ronal connections may be evidence that one normal function of
A may be to modulate synaptic connections.
In AD, corpus callosum deficits have been observed and
localized to specific regions and have been correlated with
deficits in cognitive function and metabolic activity in corre-
sponding cortical regions (62, 63). Although the corpus callosum
deficit in AD may be progressive (64–66), the etiology and the
cell populations contributing to this deficit are unknown in this
mouse model. The deficit could be a result of reduced collateral
crossing axons, a comigrating factor unrelated to APP expression
resulting from the triple strain background (61), or even a result
of A affecting glial cell function.
If the time course in this mouse model is similar to the time
course in the corresponding familial AD, more longitudinal
prospective studies are warranted, and early diagnosis strategies
criteria will have to be developed. Ultimately, AD prevalence
may be reduced by combined strategies of early diagnosis and
preventive drug therapies.
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